Stock VICO VICORE PHARMA HOLDING AB
Add to a list
To use this feature you must be a member
Log inSign up

Vicore Pharma Holding AB Stock

Equities

VICO

SE0007577895

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:39 2024-06-04 am EDT 		5-day change 1st Jan Change
23.3 SEK +1.30% Intraday chart for Vicore Pharma Holding AB +35.78% +64.32%
May. 22 Transcript : Vicore Pharma Holding AB - Special Call
May. 20 Vicore Pharma Holding AB Announces Positive Final Results from the Phase 2a Air Trial Demonstrating Buloxibutid Improves Lung Function over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis CI

Financials

Sales 2024 * 52M 4.98M Sales 2025 * 393M 37.65M Capitalization 2.6B 249M
Net income 2024 * -236M -22.6M Net income 2025 * -173M -16.57M EV / Sales 2024 * 42.5 x
Net cash position 2024 * 391M 37.47M Net cash position 2025 * 210M 20.13M EV / Sales 2025 * 6.09 x
P/E ratio 2024 *
-14.3 x
P/E ratio 2025 *
-9.91 x
Employees 26
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.02%
More Fundamentals * Assessed data

Chart Vicore Pharma Holding AB

Dynamic Chart

Latest news about Vicore Pharma Holding AB

Transcript : Vicore Pharma Holding AB - Special Call
Vicore Pharma Holding AB Announces Positive Final Results from the Phase 2a Air Trial Demonstrating Buloxibutid Improves Lung Function over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis CI
Vicore Pharma Holding AB Announces Board Appointments CI
Vicore Pharma Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Vicore Pharma Holding AB Announces Maarten Kraan, as Board Member Declined Re-Election CI
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis CI
Vicore Pharma Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Vicore Pharma Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate MT
Alex Therapeutics and Vicore Pharma Announces Positive Results of the COMPANION Study CI
Vicore Pharma Holding AB Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates CI
Vicore Pharma Holding AB Appoints Bertil Lindmark as Chief Medical Officer CI
Vicore Pharma Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Vicore Pharma Holding AB Announces the Nomination Committee for the 2024 Annual General Meeting CI
Vicore Pharma Holding AB Provides Update Regarding Phase 1 Study of C106 CI
More news

Latest transcript on Vicore Pharma Holding AB

Logo Vicore Pharma Holding AB
Vicore Pharma Holding AB - Special Call
More transcripts

Press releases Vicore Pharma Holding AB

Increase of number of shares and votes in Vicore Pharma AQ
Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis AQ
Vicore Expands and Strengthens its Board of Directors AQ
Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ) AQ
Interim report January-March 2024 AQ
More press releases

Quotes and Performance

1 day+1.30%
1 week+35.78%
Current month+5.91%
1 month+21.10%
3 months+62.03%
6 months+51.50%
Current year+64.32%
More quotes

Highs and lows

1 week
18.00
Extreme 18
24.10
1 month
16.78
Extreme 16.78
24.10
Current year
12.84
Extreme 12.84
24.10
1 year
12.36
Extreme 12.36
24.10
3 years
12.20
Extreme 12.2
37.45
5 years
6.82
Extreme 6.82
38.30
10 years
5.70
Extreme 5.7
40.00
More quotes

Managers and Directors - Vicore Pharma Holding AB

Managers TitleAgeSince
Ahmed Mousa CEO
 Chief Executive Officer 40 23-09-08
Hans Jeppsson DFI
 Director of Finance/CFO - 16-12-31
Elin Rosendahl CTO
 Chief Tech/Sci/R&D Officer - 20-11-15
Members of the board TitleAgeSince
Jacob Uno Stanley Gunterberg BRD
 Director/Board Member 57 17-12-31
Johannes G. C. P. Schikan CHM
 Chairman 66 17-12-31
Michael Buschle BRD
 Director/Board Member 64 22-12-31
More insiders

Quotes

Date Price Change Volume
24-06-04 23.3 +1.30% 535,623
24-06-03 23 +4.55% 749,049
24-05-31 22 +15.18% 1,414,509
24-05-30 19.1 +0.21% 254,212
24-05-29 19.06 +4.61% 302,921

Delayed Quote Nasdaq Stockholm, June 04, 2024 at 11:29 am EDT

More quotes

Company Profile

Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
Sector
Biotechnology & Medical Research
Calendar
2024-08-21 - Q2 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
23.3 SEK
Average target price
61.5 SEK
Spread / Average Target
+163.95%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VICORE PHARMA HOLDING AB Stock Vicore Pharma Holding AB
+64.32% 247M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.73% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+13.04% 107B
BIONTECH SE Stock BioNTech SE
-5.80% 24.82B
ARGENX SE Stock argenx SE
+1.69% 22.48B
GENMAB A/S Stock Genmab A/S
-10.09% 18.32B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.52% 16.33B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.00% 15.31B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.18% 14.08B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+24.18% 11.74B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VICO Stock